Cadila Healthcare Ltd has entered into pact for collaboration for development of a next generation therapeutic protein, 'PEG-EPO', for the treatment of severe anaemia with Prolong Pharmaceuticals Inc., a US-based, venture-backed drug delivery research and development company.
Severe Anaemia is a condition where the haemoglobin (Hb) level or number of circulating red blood cells (RBCs) is significantly reduced. This is common in chronic renal failure (CRF), cancer patients undergoing chemotherapy, some chronic inflammatory diseases, heart failure, surgical settings and critically ill patients. The first generation drug, EPO, did wonders to the treatment of this condition. However, new advances in therapy can improve EPO's therapeutic profile, offer greater convenience, and lower treatment costs. PEG-EPO promises to be a third generation drug.
Speaking on the occasion, Pankaj Patel, chairman and Managing Director Zydus Cadila, mentioned "This deal marks Zydus's foray into the area of novel improved biologicals. There is a strong unmet medical need in this space, and we are committed to discover, develop and provide better as well as safer alternatives to patients at affordable prices".
No comments:
Post a Comment